Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 74, Issue 20, Pages 2452-2462Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2019.08.010
Keywords
acute coronary syndrome; evolocumab; LDL-C; PCSK9 inhibitor
Categories
Funding
- Amgen
- Abbott
- Bayer AG
- Biotronik
- Boston Scientific
- Bristol-Myers Squibb
- CSL Behring
- Edwards Lifesciences
- Medtronic
- Sinomed
- Polares
- Sanofi
- Bayer
- Philips Volcano
- AstraZeneca
- Heartflow
- Regeneron
Ask authors/readers for more resources
BACKGROUND Although guidelines recommend in-hospital initiation of high-intensity statin therapy in patients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol (LDL-C) target levels are frequently not attained. Evolocumab, a rapidly acting, potent LDL-C-lowering drug, has not been studied in the acute phase of ACS. OBJECTIVES The purpose of this study was to assess the feasibility, safety, and LDL-C-lowering efficacy of evolocumab initiated during the in-hospital phase of ACS. METHODS The authors conducted an investigator-initiated, randomized, double-blind, placebo-controlled trial involving 308 patients hospitalized for ACS with elevated LDL-C levels ($1.8 mmol/l on high-intensity statin for at least 4 weeks; $2.3 mmol/l on low- or moderate-intensity statin; or $3.2 mmol/l on no stable dose of statin). Patients were randomly assigned 1:1 to receive subcutaneous evolocumab 420 mg or matching placebo, administered in-hospital and after 4 weeks, on top of atorvastatin 40 mg. The primary endpoint was percentage change in calculated LDL-C from baseline to 8 weeks. RESULTS Most patients (78.2%) had not been on previous statin treatment. Mean LDL-C levels decreased from 3.61 to 0.79 mmol/l at week 8 in the evolocumab group, and from 3.42 to 2.06 mmol/l in the placebo group; the difference in mean percentage change from baseline was similar to 40.7% (95% confidence interval: similar to 45.2 to similar to 36.2; p < 0.001). LDL-C levels <1.8 mmol/l were achieved at week 8 by 95.7% of patients in the evolocumab group versus 37.6% in the placebo group. Adverse events and centrally adjudicated cardiovascular events were similar in both groups. CONCLUSIONS In this first randomized trial assessing a PCSK9 antibody in the very high-risk setting of ACS, evolocumab added to high-intensity statin therapy was well tolerated and resulted in substantial reduction in LDL-C levels, rendering >95% of patients within currently recommended target levels. (EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes [EVOPACS]; NCT03287609) (J Am Coll Cardiol 2019;74:2452-62) (c) 2019 by the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available